Volume | 177,590 |
|
|||||
News | - | ||||||
Day High | 1.53 | Low High |
|||||
Day Low | 1.36 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Iterum Therapeutics PLC | ITRM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.53 | 1.36 | 1.53 | 1.41 | 1.48 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
415 | 177,590 | US$ 1.48 | US$ 262,042 | - | 0.622 - 2.64 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:37:37 | 41 | US$ 1.40 | USD |
Iterum Therapeutics PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
18.81M | 13.44M | - | 82k | -38.37M | -2.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iterum Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITRM Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.59 | 1.66 | 1.36 | 1.51 | 105,795 | -0.18 | -11.32% |
1 Month | 1.42 | 1.75 | 1.36 | 1.55 | 125,554 | -0.01 | -0.70% |
3 Months | 1.37 | 1.93 | 1.2197 | 1.54 | 167,388 | 0.04 | 2.92% |
6 Months | 1.18 | 2.64 | 1.18 | 1.62 | 399,398 | 0.23 | 19.49% |
1 Year | 1.12 | 2.64 | 0.622 | 1.55 | 222,086 | 0.29 | 25.89% |
3 Years | 1.03 | 3.1305 | 0.175 | 0.9798593 | 2,386,965 | 0.38 | 36.89% |
5 Years | 7.23 | 7.6499 | 0.175 | 1.34 | 3,445,772 | -5.82 | -80.50% |
Iterum Therapeutics Description
Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. |